12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Other News

bluebird bio, California Institute for Regenerative Medicine hematology news

CIRM awarded $9.3 million to bluebird bio under CIRM's Strategic Partnership Awards Initiative. The funds will be used to support a U.S. Phase I/II trial of LentiGlobin gene therapy to...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >